Navigation Links
Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
Date:3/30/2011

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD with pegylated interferon and ribavirin in patients with HCV genotype 1, 4, 5 or 6 who have not been treated previously.

"We are encouraged by the early efficacy and safety data being generated with our nucleotide analogs, PSI-7977 and PSI-938," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer.  "The ATOMIC trial is designed to explore 12 and 24 week durations of PSI-7977. The potency, high barrier to resistance, and consistent antiviral activity across genotypes provided the data to support an interferon free dosing period in this trial, as well as enabling us to enroll multiple genotypes in this trial."  

About the Phase 2b ATOMIC Trial

This Phase 2b trial is planned to enroll approximately 300 patients with chronic HCV genotype 1 who have not been treated previously. The primary endpoint of the trial will be the safety and tolerability of PSI-7977 in combination with peginterferon and ribavirin over 12 or 24 weeks. The trial will be conducted in the U.S. Patients will be randomized (1:2:3) into the following arms:

  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 24 weeks;
  • PSI-7977 400mg QD with peginterferon and ribavirin for 12 weeks, followed by either PSI-7977 400mg QD monotherapy for 12 weeks or PSI-7977 400mg QD plus ribavirin for 12 weeks.

HCV GT1 patients will be stratified by IL28B status and baseline HCV RNA to ensure balance across cohorts. An additional 25 treatment-naïve patients w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Webcast an Investor Event From the EASL Meeting
2. Pharmasset to Present at Three Upcoming Investor Conferences
3. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
4. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
5. Pharmasset Announces Exercise of Underwriters Overallotment Option
6. Pharmasset Prices Public Offering of Common Stock
7. Pharmasset Announces Proposed Public Offering of Common Stock
8. Pharmasset Reports Positive Results from its HCV Clinical Programs
9. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
10. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
11. Pharmasset to Webcast an Investor Event from the AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... ORANGEBURG, N.Y. , June 2, 2015 /PRNewswire/ ... products and solutions, today announced a series of ... customers about strategies to reduce the threat of ... with the US Centers for Disease Control and ... House,s National Strategy to Combat Antibiotic-Resistant Bacteria. ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( ... PharmaBiotech,s new report "Drug Delivery in Central ... to their offering. The delivery ... a challenge in the treatment of neurological disorders. ... or administered systematically (e.g., by intravenous injection) for ...
(Date:6/2/2015)... June 2, 2015 The Canadian Society for Vascular ... tests, treatments or procedures that are commonly ordered ... part of Choosing Wisely Canada.  The list identifies ... conversations between patients and physicians about what care ... for Vascular Surgery,s list identified the following five ...
Breaking Medicine Technology:PDI Partners with White House and Centers for Disease Control and Prevention (CDC) to Combat Antimicrobial Resistance 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4
... July 28, 2011 Roka Bioscience, Inc. announced today ... equity financing, raising $20 million in new capital. The ... since the company,s formation in September 2009. The investor ... Advisors, New Enterprise Associates, Inc., TPG Biotech and Gen-Probe ...
... spending growth slowed from an estimated 5.3 percent in ... data released today by the Centers for Medicare and ... Researchers credit the slowdown in spending growth to pharmacy ... toward lower cost generic drugs. Pharmaceutical Care Management ...
Cached Medicine Technology:Roka Bioscience Completes $20 Million Series C Financing 2PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:6/2/2015)... UCLA Health and Exer have completed negotiations and ... urgent care services in Los Angeles County. The ... California Board of Regents and the Exer Board of ... purchase a minority share of four existing Exer urgent ... Northridge and creates opportunity to grow and develop new, ...
(Date:6/2/2015)... New Jersey (PRWEB) June 02, 2015 ... (Horizon BCBSNJ) announced today that its Walking and Wellness ... Classic Presented by Acer, has raised another $3,000 for ... Natalie Gulbis undertook the challenge, recording 32,000 steps on ... at Stockton Seaview Hotel & Golf Club in Galloway ...
(Date:6/2/2015)... June 02, 2015 Bitscape Infotech today ... 2015 Microsoft Worldwide Small and Midsized Cloud Solutions Award. ... top Microsoft partners for demonstrating excellence in innovation and ... , “This comes as no surprise to us as ... year consecutively at worldwide level by Microsoft. We will ...
(Date:6/2/2015)... Radaris ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers can help users ... According to Psychology Today, humans are a curious species by ... is a part of human development. People are using the ...
(Date:6/2/2015)... 02, 2015 Tronics, a designer and ... growth strategy to benefit from the significant growth expected ... May 2015 Status of the MEMS Industry report, we ... reach $6.6B in 2020,” says Frederic Breussin, Business Unit ... , The analyst adds that “although the BioMEMS market ...
Breaking Medicine News(10 mins):Health News:UCLA Health Partners With Exer - More Than Urgent Care 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 2Health News:Bitscape Infotech recognized as finalist for 2015 Microsoft Worldwide small & midsized cloud solutions award. 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:Tronics Aims to Benefit from Major Growth of Sensors and Related Technologies for Healthcare Applications 2
... finds city-dwelling females have more dense breasts, , , MONDAY, Nov. ... appear to have more dense breast tissue than their suburban ... potentially important because women with more dense breasts have a ... compared rural women from Greece to suburban and urban women ...
... a smoking gun, but its smoking-related, and its there ... deep in the lungs, caused by secondhand cigarette smoke. ... to nonsmokers that was long suspected, but not previously ... suggest that their findings may strengthen public health efforts ...
... For the first time, researchers have identified structural ... , The results of the study, conducted by ... in Charlottesville and The Childrens Hospital of Philadelphia in ... the Radiological Society of North America (RSNA). , Its ...
... clinical professor of neurology at Boston University School of ... Study, was recently awarded the Stroke Council Award from ... at the AHAs recent Scientific Sessions meeting in Orlando, ... encourages those who actively work to integrate stroke and ...
... at Yale and Cornell have created a modified chemotherapy ... of brain tumors by adding a water-soluble polymer ... the November-December issue of Bioconjugate Chemistry. , This approach ... than a centimeter, which may be sufficient to prevent ...
... Imaging, a,wholly owned subsidiary of Mercury Computer Systems, ... Siemens Medical Solutions to deliver advanced,3D visualization and ... Siemens will integrate Visage Imaging,s advanced 3D ... This unique thin client-based,image distribution solution will be ...
Cached Medicine News:Health News:Urban Women May Have Greater Breast Cancer Risk 2Health News:Urban Women May Have Greater Breast Cancer Risk 3Health News:Secondhand smoke damages lungs, MRIs show 2Health News:Novel MRI technique shows secondhand smoke damages lungs 2Health News:New method of drug delivery more effective at reaching brain tumors 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 2Health News:Visage Imaging Expands Availability of Its Advanced Visualization Offering 3
Concave inner surface to conform to the globe. Used in conjunction with the E5381 600 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Medicine Products: